Upadacitinib

Strong clinical responses were observed in a small cohort of patients with hidradenitis suppurativa treated with the Janus kinase inhibitor upadacitinib, according to study findings.

More trials are needed to fully elucidate the cardiovascular, infection and malignancy risks linked to Janus kinase inhibitors in rheumatoid arthritis, said a presenter at the 2022 Association of Women in Rheumatology annual conference.

The European Commission approved Rinvoq for the treatment of patients with moderate to severe ulcerative colitis who had an inadequate response, lost response or were intolerant to conventional therapy, according to an AbbVie press release.

Acne associated with upadacitinib treatment in atopic dermatitis was generally non-severe and manageable, according to study findings.

By most metrics, modern rheumatology drugs are safer and more effective than those used in previous eras.

DESTIN, Fla. — Early treatment can provide patients with axial spondyloarthritis a better opportunity to achieve drug-free remission and slow disease progression, according to a speaker at the Congress of Clinical Rheumatology East 2022.

The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data.

The FDA has approved once-daily oral upadacitinib for the treatment of adults with active ankylosing spondylitis who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.

Despite some safety concerns, Janus kinase, or JAK, inhibitors, are carving out a place as important treatment options for a number of autoimmune diseases, including psoriatic arthritis.

Patients with psoriatic arthritis or ankylosing spondylitis who received once daily upadacitinib 15 mg experienced improvements in pain measures through 1 year, according to data published in RMD Open.